{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Enrollment",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_2",
        "name": "Run-in Period (Diet Equilibration)",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Pretreatment Balance Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Initial 15mg/day I/O Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_5",
        "name": "Steady State 15mg/day and 30mg/day I/O Collection",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 25,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_6",
        "name": "Dose Titration to 30mg/day",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_7",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_8",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_9",
        "name": "Experimental Therapy Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_10",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_11",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_12",
        "name": "Chelator Discontinuation Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_13",
        "name": "CRU Admission Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose",
        "windowLower": 0,
        "windowUpper": 0
      },
      {
        "id": "timing_14",
        "name": "CRU Re-admission Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_15",
        "name": "Urine Pregnancy Test Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "SRC Approval for Dose Titration",
        "instanceType": "Condition",
        "description": "Condition for increasing dose from 15 mg/day to 30 mg/day.",
        "text": "The Safety Review Committee (SRC) will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_2",
        "name": "ALT/AST Elevation (Moderate)",
        "instanceType": "Condition",
        "description": "Liver enzyme elevation criteria for dose modification.",
        "text": "ALT or AST > 3 × ULN and ≤ 5 × ULN"
      },
      {
        "id": "cond_3",
        "name": "ALT/AST Elevation (Severe)",
        "instanceType": "Condition",
        "description": "Liver enzyme elevation criteria for discontinuation.",
        "text": "ALT or AST > 5 × ULN"
      },
      {
        "id": "cond_4",
        "name": "Thrombocytopenia",
        "instanceType": "Condition",
        "description": "Low platelet count criteria for dose modification.",
        "text": "Platelets < 100,000/mm^3"
      },
      {
        "id": "cond_5",
        "name": "Anemia",
        "instanceType": "Condition",
        "description": "Low hemoglobin criteria for dose modification.",
        "text": "Hemoglobin < 10 g/dL"
      },
      {
        "id": "cond_6",
        "name": "Neutropenia",
        "instanceType": "Condition",
        "description": "Low neutrophil count criteria for dose modification.",
        "text": "Neutrophils > 30% decrease from baseline and below reference range"
      },
      {
        "id": "cond_7",
        "name": "Potential Liver Injury",
        "instanceType": "Condition",
        "description": "Bilirubin and ALT elevation criteria for dose modification.",
        "text": "Bilirubin > 2 × ULN accompanied by ALT > 3 × ULN"
      },
      {
        "id": "cond_8",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Clinical sign of neurologic worsening.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_9",
        "name": "Pregnancy",
        "instanceType": "Condition",
        "description": "Condition for discontinuing study intervention.",
        "text": "Participant becomes pregnant or is planning a pregnancy."
      },
      {
        "id": "cond_10",
        "name": "Adaptive Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "Adaptive design feature allowing for extension of the outpatient period.",
        "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Enrollment",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_treatment",
        "text": "Participants who sign the informed consent form (ICF), are eligible for the study, and are registered on Day -7 are considered enrolled."
      },
      {
        "id": "trans_2",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Participants will be administered ALXN1840 at 30 mg/day on Day 29, following a favorable safety review by the SRC."
      },
      {
        "id": "trans_3",
        "name": "Dose Interruption for Moderate ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3x ULN and <= 5x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_4",
        "name": "Discontinuation for Severe ALT/AST Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT or AST > 5x ULN, discontinue study intervention."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Thrombocytopenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Platelets < 100,000/mm^3, temporarily interrupt dosing."
      },
      {
        "id": "trans_6",
        "name": "Dose Interruption for Anemia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Hemoglobin < 10 g/dL, temporarily interrupt dosing."
      },
      {
        "id": "trans_7",
        "name": "Dose Reduction for Neutropenia",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Neutrophils > 30% decrease from baseline and below reference range, reduce dose to previous dose level or to 15 mg QOD."
      },
      {
        "id": "trans_8",
        "name": "Dose Interruption for Potential Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN with ALT > 3x ULN, temporarily interrupt dosing."
      },
      {
        "id": "trans_9",
        "name": "Dose Modification for Neurologic Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease) based on neurologic worsening."
      },
      {
        "id": "trans_10",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention if pregnancy or planned pregnancy occurs."
      },
      {
        "id": "trans_11",
        "name": "Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for use of disallowed medication."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted by the study site."
      },
      {
        "id": "exit_5",
        "name": "Sponsor or Investigator Study Termination",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion or the Investigator may close the study site or terminate the study at any time for reasons such as failure to comply with protocol, inadequate recruitment, or discontinuation of study intervention development."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Escalation Decision",
        "timepointId": "pt_day29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point on Day 29 to escalate dose from 15 mg/day to 30 mg/day, based on SRC review of safety data collected through Day 23.",
        "conditionIds": [
          "cond_1"
        ]
      },
      {
        "id": "dec_2",
        "name": "Ongoing Safety Monitoring Decision",
        "timepointId": "pt_ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing assessment of safety parameters that may trigger dose modification or discontinuation of study intervention at any time during the study.",
        "conditionIds": [
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8",
          "cond_9"
        ]
      }
    ],
    "summary": {
      "timingCount": 15,
      "conditionCount": 10,
      "transitionRuleCount": 11,
      "exitCount": 5
    }
  }
}